Gilead gets FDA priority review of Hepatitis C combo drug
January 04, 2016 at 18:52 PM EST
Gilead Sciences said the U.S. Food and Drug Administration granted a priority review of its experimental hepatitis C combination drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.